Short answer
Natera Inc (NTRA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $794M (up 34.1% year over year) with net income of −$60M.
Q3 2026 key financials · XBRL
- Revenue
- $794M
- +34.1% YoY · +5.5% QoQ
- Net income
- −$60M
- +31.6% YoY · +10.5% QoQ
- Operating margin
- -8.6%
- EPS (diluted)
- −$0.41
- +35.9% YoY · +12.8% QoQ
Source: XBRL data from the Natera Inc (NTRA) Q3 2026 10-Q on SEC EDGAR. USD.
Natera Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $794.0M, up 34.1% YoY from $592.2M
- Product revenue $790.0M, up 33.9%; oncology units 339,500 vs 211,000
- Product cost margin 64.6% vs 64.9% YoY, with net loss $59.9M vs $87.5M
- Cash $1.1B; operating cash flow $138.9M, down from $141.4M; capital spending $124.2M
- Outlook: continued net losses, heavy R&D investment, potential need for additional equity or debt financing
Risk Factors
- No material changes reported from the December 31, 2025 Form 10-K
- Carried-forward business risk: disclosed 10-K risks could materially adversely affect operations and prospects
- Market risk: adverse developments could reduce common-stock price and investor returns
- Disclosure risk: additional unknown or currently immaterial risks could materially harm results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.